Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000653141 | SCV000775017 | pathogenic | Dyskeratosis congenita, autosomal recessive 6; Pulmonary fibrosis and/or bone marrow failure, Telomere-related, 4 | 2025-01-11 | criteria provided, single submitter | clinical testing | This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 91 of the PARN protein (p.Tyr91Cys). This variant is present in population databases (rs201765587, gnomAD 0.02%). This missense change has been observed in individual(s) with Hoyeraal Hreidarsson syndrome (PMID: 31448843; internal data). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 542669). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt PARN protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects PARN function (PMID: 31448843). For these reasons, this variant has been classified as Pathogenic. |
Bertuch Lab, |
RCV000850488 | SCV000902456 | pathogenic | Dyskeratosis congenita, autosomal recessive 6 | 2019-05-15 | criteria provided, single submitter | in vitro | PARN is a ribodeadenylase. Biallelic PARN variants have been reported in 9 cases of Hoyeraal-Hreidarsson syndrome (HH)/dyskeratosis congenita. Monoallelic PARN variants are associated with IPF and more than 50 cases have been reported. This rare missense variant, p.Y91C, and novel insertion variant, p.I274*, were found in trans in two siblings with HH. Unaffected family members did not have both variants. Functional studies showed that PARN p.Y91C had reduced deadenylase activity and the p.I274* transcript likely underwent NMD. Studies with patient-derived samples showed the expected alteration of PARN target RNAs in one affected sibling. Telomere lengths were extremely short for both affected siblings. However, monoallelic variant carriers had variable telomere length, indicating incomplete penetrance of short telomeres in PARN variant carriers. In summary, this variant has strong evidence for being pathogenic according to ACMG 2015 guidelines and functional data, segregation data, and allelic data. |
Genetic Services Laboratory, |
RCV001816642 | SCV002068936 | uncertain significance | not specified | 2019-11-14 | criteria provided, single submitter | clinical testing | |
Ai |
RCV002223900 | SCV002502206 | likely pathogenic | not provided | 2022-03-09 | criteria provided, single submitter | clinical testing | |
Genetics and Molecular Pathology, |
RCV003447549 | SCV004175270 | uncertain significance | Pulmonary fibrosis and/or bone marrow failure, Telomere-related, 4 | 2023-07-05 | criteria provided, single submitter | clinical testing | The PARN c.272A>G variant is classified as VUS (PS3_Moderate) The PARN c.272A>G variant is a single nucleotide change in exon 5/24 of the PARN gene, which is predicted to change the amino acid tyrosine at position 91 in the protein to cysteine. This variant is present at low frequency in population databases (gnomAD allele frequency = 0.0091%; 14 het and 0 hom in 152186 sequenced alleles; highest frequency = 0.019%, East Asian population) (PM2 not met). Computational predictions provide conflicting interpretations of pathogenicity for this variant (PP3 and BP4 not met). Functional studies showed that the p.(Tyr91Cys) variant had reduced deadenylase activity (10-fold lower than WT). The Y91C-mutated PARN polypeptide was perturbed in its deadenylation activity and suggest that the PARN-mediated deadenylation activity in individuals in this pedigree carrying the mutation was affected. However, the affected pedigree shows pseudo-dominant inheritance, and the heterozygous carriers of the Y91C variant only displayed reduced telomeres, without bone marrow failure (Dodson et al, 2019; PMID:31448843). (PS3_moderate). The variant has been reported in dbSNP (rs201765587) and in the HGMD database: CM1918160. It has been reported as Pathogenic by other diagnostic laboratories (ClinVar Variation ID: 542669). |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003994067 | SCV004813933 | likely pathogenic | PARN-related disorder | 2024-02-05 | criteria provided, single submitter | clinical testing | Variant summary: PARN c.272A>G (p.Tyr91Cys) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 7e-05 in 243878 control chromosomes. c.272A>G has been reported in the literature in trans along with a pathogenic variant in PARN in two siblings affected with Hoyeraal-Hreidarsson syndrome, other family members carrying this variant reported healthy but had reduced levels of lymphocyte telomeres (example, Dodson_2019). The variant was also reported as a de novo change in one individual from a cohort of Autism patients, without sufficient information for independent analysis (Zhou_2022). These data indicate that the variant may be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal deadenylation activity in vitro (Dodson_2019). The following publications have been ascertained in the context of this evaluation (PMID: 31448843, 35982159). ClinVar contains an entry for this variant (Variation ID: 542669). Based on the evidence outlined above, the variant was classified as likely pathogenic. |